Fierce Pharma
SEPTEMBER 7, 2023
Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. | Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.
MedCity News
SEPTEMBER 7, 2023
By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
SEPTEMBER 7, 2023
Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. | Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.
MedCity News
SEPTEMBER 7, 2023
A new survey from Alignment Health found that economic instability, food insecurity, lack of support and transportation access are the biggest social barriers for seniors.
Fierce Pharma
SEPTEMBER 7, 2023
University of Pennsylvania spinout BlueWhale Bio has surfaced on a mission to smash bottlenecks in cell and gene therapy manufacturing. | Cell therapy manufacturer BlueWhale Bio uncloaked Thursday with news it has raised $18 million in seed financing. The funding round was led by Danaher Corporation.
Healthcare Success
SEPTEMBER 7, 2023
Today, the marketing spotlight often shines on Millennials, Gen Z, and Gen X due to their vast numbers, combined influence, and economic power. However, marketing to Baby Boomers remains vitally important. At approximately 68.6 million strong, Baby Boomers remain a formidable and highly-valuable consumer segment. Unfortunately, when building their marketing strategies, many marketers fail to truly understand Baby Boomers, including their rich and nuanced history, disposable income, diversity, an
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 7, 2023
Medicare Advantage beneficiaries with a cancer diagnosis spend $3,996 on out-of-pocket costs and premiums annually, versus $6,091 for traditional Medicare beneficiaries with cancer, a new report found.
Fierce Pharma
SEPTEMBER 7, 2023
Johnson & Johnson’s plan to expand decade-old pulmonary hypertension med Opsumit has hit a snag. | J&J’s Janssen has decided to stop a phase 3 trial for a high dose of Opsumit in a subtype of pulmonary hypertension. With the flop, J&J loses a chance to challenge Bayer's Adempas.
Clarivate
SEPTEMBER 7, 2023
We are proud to introduce fresh insights into measuring global research performance via our dynamic G20 scorecard for 2023, newly enhanced with online data visualizations. This guide to understanding the G20 scorecard explores how this interactive tool expands our perspective of global research and innovation. Each year, prior to the G20 Summit of the heads of state of the member nations, the Institute for Scientific Information (ISI) at Clarivate releases its annual G20 scorecard.
Fierce Pharma
SEPTEMBER 7, 2023
Thanks to a contract manufacturing deal with Takeda gone awry, AbbVie appears to be in line to receive hundreds of millions of dollars in damages. | The Delaware Court of Chancery sided with AbbVie in the damages portion of the case, granting the drugmaker nearly all of the $480.6 million it was seeking over a botched supply agreement for Lupron.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
SEPTEMBER 7, 2023
This week, Abbott announced its plans to acquire Bigfoot Biomedical — a startup selling a “smart” insulin pen cap, which collects data from a user’s CGM to help them calculate the right dose. Most analysts were unsurprised to hear of the acquisition given that the two companies have been collaborating for more than six years, but they said the deal reinforces the steady pace of digital innovation in the diabetes care space.
Fierce Pharma
SEPTEMBER 7, 2023
PhRMA has rounded up its attack ad team once again for another broadside against pharmacy benefit managers, zeroing in this time on the potential for insurers to profit from where prescriptions get | PhRMA has rounded up its attack ad team once again for another broadside against pharmacy benefit managers, zeroing in this time on the potential for insurers to profit from where prescriptions get filled.
PharmaTimes
SEPTEMBER 7, 2023
The trial analyses the impact of its ‘Neuro-Cells’ among patients with traumatic spinal cord injuries - News - PharmaTimes
Fierce Pharma
SEPTEMBER 7, 2023
After 10 years on the market, the Bristol Myers Squibb and Celgene blockbuster multiple myeloma treatment Pomalyst has landed in some legal hot water. | Blue Cross and Blue Shield of Louisiana claims the drug giant used sham patents and lawsuits to extend its Pomalyst monopoly. The insurer seeks a jury trial and compensation for overpayments.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PM360
SEPTEMBER 7, 2023
Since 2020, diversity, equity, and inclusion (DE&I) has been a prime area of attention within healthcare and the life sciences. For one, the pandemic put a spotlight on the disparity within clinical trials—in 2020 the FDA found that 75% of trial participants were white, 11% were Hispanic, 8% were Black, and 6% were Asian. Furthermore, the rise of the Black Lives Matter movement at the time forced organizations in all industries to take a closer look at their DE&I efforts and inspired som
Fierce Pharma
SEPTEMBER 7, 2023
Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.
PM360
SEPTEMBER 7, 2023
The healthcare system might not be too keen to hang this report card on the fridge: 26% of Americans rated their healthcare experience as a D (18%) or an F (8%), while 34% gave it a solid C and only 10% gave it an A, that’s according the American Academy of Physician Associates (AAPA) and The Harris Poll’s survey of 2,519 adults age 18+ conducted between February 23 and March 9, 2023. 1 For 65% of respondents, one of the biggest issues was that coordinating and managing healthcare is overwhelmin
Fierce Pharma
SEPTEMBER 7, 2023
Eli Lilly has been riding the success of its new diabetes drug Mounjaro since its U.S. debut last May. Now, the company and its star medicine are set for a boost across the pond. | The nod comes after the agency initially declined to sign off on the drug due to uncertainties with Mounjaro's efficacy and cost-effectiveness.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
SEPTEMBER 7, 2023
Seagen and Nurix are bringing their respective technologies together to develop a new class of cancer drugs called degrader antibody conjugates. Nurix CEO Arthur Sands says the multi-year, multi-target collaboration expands the reach of each company’s technology.
Fierce Pharma
SEPTEMBER 7, 2023
After a clutch of lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book—the registry for patents of approved drugs—the Federal Trade Commission (FTC) is getting in on | After multiple lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book, the FTC is getting in on the action.
Medgadget
SEPTEMBER 7, 2023
Researchers at the University of California San Diego have created a bacterial sentinel system that can alert clinicians to the presence of tumors. The technology takes advantage of the specificity of the CRISPR system and the tendency of bacteria to uptake fragments of DNA from their environment. Termed “Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer” (CATCH), the system has been created to detect gastrointestinal tumors in its first iteration.
PM360
SEPTEMBER 7, 2023
The “Kama Sutra” for Parkinson’s patients. A card game designed to help hemophilia patients exercise. A virtual product launch for patients akin to an iPhone debut. Documentaries, children’s books, Marvel comics, and interactive zines. All of these are examples of how companies are taking a little more unconventional approach to patient engagement. “The notion of radical empathy is something that has guided us when engaging patients,” says Ryan Mason, Chief Marketing and Creative Officer, Fishaw
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
MedCity News
SEPTEMBER 7, 2023
The President’s Council of Advisors on Science and Technology (PCAST) issued a report that laid out four recommendations to improve patient safety across the nation. Some of these included creating federal leadership positions focused on advancing patient safety and hastening research on systems of safe care.
PM360
SEPTEMBER 7, 2023
PM360 asked experts in delivering optimal patient experiences how the industry can better understand what patients need and what is likely to be the biggest change to how patients experience healthcare in the coming years. Specifically, we wanted to know: How can life sciences companies and marketers develop fuller, more complete pictures of patients to better serve their needs and deliver better experiences?
European Pharmaceutical Review
SEPTEMBER 7, 2023
A Phase I trial employing the drug dasatinib has shown promise in clearing senescent cells in Alzheimer’s. Recent drugs targeting beta-amyloid plaques have only yielded modest results, according to the study researchers. Instead, the current US study pursued cellular senescence as an alternative area of focus. The findings published in Nature Medicine described how the US Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor dasatinib was used in combination with quercetin, a pla
Medgadget
SEPTEMBER 7, 2023
Researchers at Washington University School of Medicine have developed a COVID-19 breathalyzer test. The technology requires someone to breathe into it just once or twice, and it can then provide an indication if the person is infected with SARS-CoV-2 in as little as one minute. The device could be very useful fo screening large numbers of people prior to access to an indoor event, for instance, or in community clinics to quickly determine if people are infected.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
European Pharmaceutical Review
SEPTEMBER 7, 2023
Leveraging PAT for environmental monitoring in light of Annex 1 The pharma industry’s adaptation to Industry 4.0 has been slow, due to the extensive regulatory requirements imposed on manufacturers. However, regulatory agencies are starting to embrace movement towards more rapid/automated systems, as illustrated in the revised EU GMP Annex 1, which is due to enter into force in August.
PharmaTimes
SEPTEMBER 7, 2023
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact - News - PharmaTimes
European Pharmaceutical Review
SEPTEMBER 7, 2023
How breakthrough CAR-T cancer therapies could be made more widely accessible The development and regulatory approval of the first autologous CAR T-cell therapies is a huge advance for modern medicine and has been greeted with justifiable excitement. But applications of this technology are still limited, and given the time and cost constraints, more must be done to broaden access to this treatment.
Pharmaceutical Technology
SEPTEMBER 7, 2023
Veracyte has announced a partnership with Gustave Roussy to support biopharmaceutical companies in expediting the development
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
324 
Let's personalize your content